linjc16/ctgov huggingface dataset:
Integrating a Suite of Mental Health Apps for Depression in a Healthcare Setting

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the implementation of IntelliCare as a frontline intervention within health care settings.

Detailed Description
-----------------
This study will evaluate the implementation of IntelliCare in two settings: Primary care in the McLeod Health system, serving a rural population where mental healthcare workers are scarce, and Northwestern Medicine's Department of Psychiatry, which currently has a 9-month waitlist for psychological services.

Official Title
-----------------
Integrating a Suite of Mental Health Apps for Depression in a Healthcare Setting

Conditions
-----------------
Depression, Anxiety

Intervention / Treatment
-----------------
* Behavioral: IntelliCare


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who have been identified as depressed or anxious by a care provider in one of the participating healthcare organizations. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: IntelliCare<br>8 weeks of IntelliCare | Behavioral: IntelliCare<br>* A mobile intervention that use principles of computerized therapy to decrease symptoms of depression<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reach | 1. Number of eligible patients during trial period; 2) number offered IntelliCare; 3) number initiating IntelliCare; 4) number completing IntelliCare | 5 months | 
| Cost | Cost of delivering IntelliCare per patient | 7 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Depression | Patient Health Questionnaire-9 (PHQ-9); higher scores indicate greater symptom severity | Administered weekly over 8 weeks |
Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection

Study Overview
=================
Brief Summary
-----------------
Currently, it is the standard of care practice to perform daily routine CXR when a chest tube is in situ following pulmonary resection. However, previous research as well as experience of thoracic surgeons suggested this kind of management has poor diagnostic and therapeutic value. Eliminating daily routine CXR for adult patients having undergone pulmonary surgery might decrease the frequency of radiation exposure and hospitalization costs per patient without increasing reintervention rates, length of hospital stays, readmission rates or any adverse events.

Official Title
-----------------
A Randomized Controlled Feasibility Study Looking at Differences in Hospital Stay Variables Following Omission of Daily Routine Chest Radiographs After Pulmonary Resection.

Conditions
-----------------
Lung Cancer, Lung Diseases, Lung Cancer, Nonsmall Cell, Surgery, Lung Adenocarcinoma

Intervention / Treatment
-----------------
* Diagnostic Test: Chest Xray
* Diagnostic Test: No daily chest xray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult males or females who plan to receive VATS pulmonary resections confined to lobectomies, segmentectomies and wedge resections. Willingness to adhere to randomized treatment. Ability to answer self- and interviewer- administered questions in English Understand and sign a written informed consent form in English Exclusion Criteria: Previous thoracic surgery history in the same side. Exploration, biopsy, lung volume reduction surgeries (LVRS), bilobectomies, sleeve resections or pneumonectomies performed.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Daily Chest Xray (standard)<br> | Diagnostic Test: Chest Xray<br>* Daily chest xray<br>|
| Experimental: Chest Xray post chest tube removal only<br> | Diagnostic Test: No daily chest xray<br>* Chest xray will be done post chest tube removal only<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of total chest xrays performed per subject | number of scheduled and additional chest xrays, and how does this correlate with post operative safety | 30 days |
Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management

Study Overview
=================
Brief Summary
-----------------
To assess the pattern of hypertension in the population in terms of presence of additional risk factors (ARF) and cardiovascular risk stratification.

Detailed Description
-----------------
routine physician visits

Official Title
-----------------
Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Other: Usual Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 to 80 years old Patients with hypertension: newly diagnosed and /or already diagnosed and treated , whether at goal or not for the blood pressure level; Patients with no history of CHD/CVD Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hypertensive Subjects undergoing primary prevention<br> | Other: Usual Care<br>* Normal care for hypertensive patients with risk factors for CHD<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of hypertensive patients in terms of presence of associated cardiovascular (CV) risk factors (number of additional CV risk factors and frequency) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of pattern of management of HT and CVD prevention, through lifestyle and use of drug therapies, |  |  | 
| Estimate adherence to treatment using the Morisky Adherence Scale (MAS) |  |  | 
| Estimation of hypertensive patients CV risk stratification based on ESH/ESC Hypertension Guidelines 2007 and to compare it with physicians' estimation of CV risk. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Epidemiology, hypertension, risk factors, coronary heart disease, patient management, compliance with medication
Robotic MIS With Dexter

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to confirm the perioperative and early postoperative safety and clinical performance of the Dexter Robotic System (Dexter Surgical System, Model DM-L6).

Official Title
-----------------
Robotic Minimally Invasive Gynecological, Urological, and General Surgery With Dexter

Conditions
-----------------
Hysterectomy, Partial Nephrectomy, Right Colectomy

Intervention / Treatment
-----------------
* Device: robotic-assisted surgery
* Device: robotic-assisted surgery
* Device: robotic-assisted surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years Patient agrees to perform the 30-day follow-up assessment Able to provide signed Informed Consent, according to local regulation Exclusion Criteria: Morbidly obese patients. Any and all relative and absolute contraindications to endoscopic surgical technique applicable to the use of conventional endoscopic surgical instruments. Bleeding diathesis. Pregnancy. Patients with pacemakers or internal defibrillators. Any planned concomitant procedures. Patient deprived of liberty by administrative or judicial decision or under legal guardianship. Participation in another interventional clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: robotic-assisted surgery|Gynecology: robot-assisted and laparoscopic hysterectomy for benign or low risk malignant disease|
|Device: robotic-assisted surgery|Urology: robot-assisted and laparoscopic partial nephrectomy|
|Device: robotic-assisted surgery|General surgery: robot-assisted and laparoscopic right colectomy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| occurrence of serious (Clavien - Dindo grades III-V), device related adverse events. |  | perioperatively up to 30 days | 
| successful completion of the Dexter-assisted procedure, i.e. free of any device related permanent conversion to an open or fully laparoscopic surgical approach. |  | intraoperative |
Prognosis in Pregnant With COVID-19

Study Overview
=================
Brief Summary
-----------------
COVID-19 is a disease whose development, prognosis mechanism and immune status are still unknown. The aim of the study is to determine the relationship between clinical and laboratory data and the severity of the disease by evaluating the hematological and radiological features of the patients. The secondary aim is to determine the predictive values of clinical and laboratory data for the severity of COVID-19.

Official Title
-----------------
Prognostic Factors in Pregnant Women With COVID-19

Conditions
-----------------
COVID-19, Prognostic Factors, Pregnancy

Intervention / Treatment
-----------------
* Diagnostic Test: imaging, blood tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being pregnant with a diagnosis of COVID-19 between the ages of 18-45 Exclusion Criteria: Suspected COVID-19 diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: imaging, blood tests|PCR and CT results, hemogram, urea, creatinine, AST, ALT, LDH, D-Dimer, ferritin, lipase, amylase, CRP, procalcitonin, albumin, total protein, coagulation tests-PT, APTT, Fibrinogen-, Troponin T, CK , electrolytes, blood gas, bilirubins|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the factors affecting prognosis in pregnant women diagnosed with COVID-19 |  | 3 Months |
Low-cost, Noninvasive Method to Assess Pulpal Vitality

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to find a new way of using light to measure the blood flow within the tooth. The researcher develop dental Laser Speckle imaging system tool that can use for exam condition of the tooth. This device is reliable method to provide information to dentists and endodontists during oral examination.

Detailed Description
-----------------
In additional to routine oral exam the researcher can use the Laser Speckle imaging system probe with low-level light shine to the problematic tooth to collect blood flow information.

Official Title
-----------------
Low-cost, Noninvasive Method to Assess Pulpal Vitality

Conditions
-----------------
Other Dental Disease/Condition of Teeth/Supporting Structure

Intervention / Treatment
-----------------
* Other: problematic tooth


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged 18 to 30. Have one or more teeth requiring endodontic treatment. Exclusion Criteria: Participation in other study within 3 months of enrollment in this study, Pregnant Women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: problematic tooth|problematic tooth|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Healthy tooth | Healthy tooth | up to 4 weeks |
Perinatal Outcome After Premature Rupture of Membranes

Study Overview
=================
Brief Summary
-----------------
Premature rupture of membranes is an important cause of neonatal morbidity and mortality, mainly because of the complications associated with this pathology (oligohydramnios, cord compression or prolapse, infection). When rupture of the membranes occur the risk of cord compression increases but there is little evidence regarding this complication and amniotic fluid volume. The investigator's focus are the perinatal outcomes according to amniotic fluid volume (< 5 or >5).

Official Title
-----------------
Perinatal Outcomes According to Amniotic Fluid Indez After Premature Rupture of Membranes. A Prospective Cohort Study.

Conditions
-----------------
Fetal Membranes, Premature Rupture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational age between 24-34 weeks. Confirmed diagnosis of premature rupture of membranes. Exclusion Criteria: Twin pregnancies. Obstetric pathologies that require immediate termination of pregnancy (severe preeclampsia, abruptio placenta, cord prolapse). Termination of pregnancy (whatever the reason) before complete corticoid treatment. Incomplete recollection of all data required for analysis.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Amniotic Fluid Volume > 5<br>Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index above 5.1 | |
| Amniotic Fluid Volume < 5<br>Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index of 5 or less. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cesarean section rate | Number of cases in each cohort that were interrupted by cesarean section due to fetal distress (evidence of cord dystocia). | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perinatal mortality | Number of perinatal deaths (ante, peri and postpartum until 28 days postpartum)in each cohort. | 5 months | 
| Neonatal sepsis | Number of cases of neonates diagnosed with sepsis in each cohort. | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fetal membranes, premature rupture, Cesarean section, Perinatal mortality, Neonatal sepsis, Amniotic Fluid Volume
Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous

Study Overview
=================
Brief Summary
-----------------
Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups. Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.

Detailed Description
-----------------
Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups. Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent. The study will record the clinical characteristics of the homozygous Hgb C patients and the hematology characteristics of all the heterozygous carriers detected in northern Israel

Official Title
-----------------
Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous

Conditions
-----------------
Hgb C Hemoglobinopathy

Intervention / Treatment
-----------------
* Procedure: Medical history and basic laboratory analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients diagnosed as homozygous for Hgb C disease or double heterozygous in combination to other abnormal hemoglobin, and all the carriers detected in the hematology laboratory during the screening for abnormal hemoglobins in northern Israel
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Medical history and basic laboratory analysis|Medical history and basic laboratory analysis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hgb C, Screening
VR Sedation in Third Molar Surgery

Study Overview
=================
Brief Summary
-----------------
Anaesthesia or sedation for dental surgery is Challenging. Over-sedation, leading to upper airway obstruction, desaturation and apnoea, is very common. On the other hand, it is also very common that inadequate sedative drugs were given, leading to under-sedation with unsatisfactory experience during operation. Therefore, it is good if some other methods are provided for sedation, avoiding side effects associated with sedative drugs.

Detailed Description
-----------------
Immersive virtual reality (VR) is a form of distraction therapy and is believed to create an immersive experience that can restrict the mind from pain and anxiety and has been shown to be superior to simple distraction in reducing pain.

Official Title
-----------------
Sedation Sparing Effect of Virtual Reality in Third Molar Surgery

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Drug: Propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Unilateral impacted lower third molar that requires surgical removal Depth of impaction within 8mm as measured by Winter's line. Cantonese speaking Exclusion Criteria: ASA > III BMI > 35 Known Obstructive Sleep Apnoea Patients with known or potential difficult airway Chronic use of sedatives and opioid Alcohol or drug abuse Visual and hearing impairments Claustrophobia Cognitive impairment History of seizure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VR group<br>VR program will be displayed throughout the surgery. | Drug: Propofol<br>* Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.<br>|
| Placebo Comparator: Non-VR group<br>VR program will be turned off throughout the surgery. | Drug: Propofol<br>* Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraoperative propofol dose | Amount of propofol required during surgery | From the start of anaesthesia to the end of anaesthesia, up to 2 hours after the start of surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anaesthesia for dental surgery, Sedation for dental surgery